Head-To-Head Review: Baxter International (NYSE:BAX) and Motus GI (NASDAQ:MOTS)

Motus GI (NASDAQ:MOTS) and Baxter International (NYSE:BAX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Motus GI and Baxter International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Motus GI	-3,239.75%	-1,731.08%	-115.99%
Baxter International	16.51%	18.06%	5.21%

Earnings & Valuation

This table compares Motus GI and Baxter International”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Motus GI	$320,000.00	0.01	-$12.87 million	($15.64)	0.00
Baxter International	$11.77 billion	1.47	$2.66 billion	$0.20	169.15

Baxter International has higher revenue and earnings than Motus GI. Motus GI is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

20.1% of Motus GI shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 0.3% of Motus GI shares are owned by company insiders. Comparatively, 0.2% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Motus GI and Baxter International, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Motus GI	0	0	0	0	0.00
Baxter International	1	7	3	0	2.18

Baxter International has a consensus price target of $40.91, indicating a potential upside of 20.93%. Given Baxter International’s stronger consensus rating and higher possible upside, analysts clearly believe Baxter International is more favorable than Motus GI.

Volatility & Risk

Motus GI has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Summary

Baxter International beats Motus GI on 12 of the 14 factors compared between the two stocks.

About Motus GI

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

About Baxter International

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company’s products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.